Fore Biotherapeutics

Precision Oncology Treatments

Health Tech & Life Sciences
Active
Series D Jerusalem Founded 2011
Total raised
$153.5M
Last: Series D 2023-08
Stage
Series D
Founded
2011
Headcount
51
HQ
Jerusalem
Sector
Health Tech & Life Sciences

About

Fore Biotherapeutics is a precision oncology company using functional genomics to pioneer treatments that improve the lives of patients with rare cancers. Using its functional genomics platform, the company is hyper-targeting therapies for unaddressed tumor mutations to benefit patients with few therapeutic alternatives. Its mission is to provide one-to-one matching between patients and new treatments tailored to them while providing broad access with speed and quality.

Fore’s proprietary functional genomics capabilities, called Foresight, are elucidating disease biology to deliver hyper-targeted treatments to patients with unaddressed tumor mutations. Newly identified driver mutations are retested through Foresight for their response to different compounds. Compounds that reduce oncogenic signaling pathway activity are flagged as potential drug candidates, generating a range of potential new therapeutic applications.

Funding history · 6 rounds · $153.5M total

2023-08
Series D $75.0M
2020-09
Series C $57.0M
2018-04
Debt Financing $6.0M
2016-06
Series B $12.5M
2015-12
Series A $2.0M
2013-07
Seed $2.0M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenesArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B

Highlights

1 Patents

Tags

personalizationoncologycancerpharmaceuticalsgenomicstargeted-therapypatientsartificial-intelligencedrug-discoverymachine-learningtherapeuticscancer-therapy